SciELO - Scientific Electronic Library Online

vol.61 issue2A prospective interventional study on comorbidities, drug - drug interactions and its management among cancerTechnological development of sodium heparin injection in solution of 5.000 IU/mL author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Ars Pharmaceutica (Internet)

On-line version ISSN 2340-9894


BARROS, Gabriel Romero Melo do Rêgo et al. Financial impact of antibiotic therapy face to bacterial multiresistance in emergency hospital in Pernambuco, Brazil. Ars Pharm [online]. 2020, vol.61, n.2, pp.121-126.  Epub July 20, 2020. ISSN 2340-9894.


The objective of this article was to analyze the financial costs of antibiotic therapy against bacterial resistance in a public hospital of high complexity located in the Agreste region of Pernambuco.


It was performed a descriptive, retrospective and cross-sectional study based on data collected from Hospital Infection Control Commission (CCIH) and the Pharmaceutical Supply Center (CAF) of the investigated hospital. It was obtained by a structured instrument of data collection and the period analysed was from January to December 2016.


The main clinical samples with presence of bacterial multiresistance were blood, urine and tracheal secretion, with a higher prevalence of the following bacteria: Staphylococcus aureus(23,08%), Coagulase-negative Staphylococcus(26,15%), Citrobactersp. (19,23%), Enterobactersp. (10,77%) and Pseudomonassp (7,69%). Faced to the multiresistance presented, the most common antibiotics used in the treatment were: vancomycin (21,7%), piperacillin-tazobactam (24,55%), ampicillin-sulbactam (10,4%), cefepime (18,43%) and meropenem (58,5%). The presence of resistant bacteria was a cause of increased costs in the treatment of patients. According to this study, the antibiotic therapy listed above generated a cost of R$ 83.298,83 and 49% of hospital death in 2016.


The prevention, through of policies related to the control and rational use of antimicrobials, is fundamental in the fight against hospital infections caused by multiresistant bacteria.

Keywords : Bacteria; Drug Resistance Microbial; Hospital Costs.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )